Insurer plans $4B investment blitz to add lab space outside of U.S. biotech hot spotsnews2022-05-25T08:22:52+00:00May 25th, 2022|FierceBiotech|
ASCO: I-Mab, Junshi’s cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarkernews2022-05-24T21:40:47+00:00May 24th, 2022|FierceBiotech|
ASCO: J&J’s multiple myeloma toolkit expands with bispecifics datanews2022-05-24T16:28:24+00:00May 24th, 2022|FierceBiotech|
CSL Behring gene therapy makes comeback after hold for FDA priority reviewnews2022-05-24T14:29:16+00:00May 24th, 2022|FierceBiotech|
Genocea closes up shop after failing to find a buyer, delists from Nasdaqnews2022-05-24T14:18:23+00:00May 24th, 2022|FierceBiotech|
Manufacturing concerns sideline INmune’s US Alzheimer’s trialnews2022-05-24T13:46:53+00:00May 24th, 2022|FierceBiotech|
Supply chain challenges upend Caladrius’ coronary artery disease trialnews2022-05-24T13:24:47+00:00May 24th, 2022|FierceBiotech|
When will biotech markets get better? BridgeBio fears they may stay ‘pretty bad’ until 2024news2022-05-24T12:39:00+00:00May 24th, 2022|FierceBiotech|
Boing! SpringWorks’ stock jumps as phase 3 tumor trial hits goalnews2022-05-24T11:23:22+00:00May 24th, 2022|FierceBiotech|
Moderna tunes vaccine platform to next potential viral threat: monkeypoxnews2022-05-23T20:33:48+00:00May 23rd, 2022|FierceBiotech|
